Global Pediatric Drugs Market – Industry Trends and Forecast to 2029

Análisis y tamaño del mercado

En los últimos años, se prevé que el mercado de medicamentos pediátricos crezca rápidamente durante el período de pronóstico. Para 2020, se prevé que mueran 5,0 millones de niños menores de cinco años, según el Informe 2020 del Fondo Internacional de Emergencia para la Infancia de las Naciones Unidas (UNICEF). Esto equivaldría a 13.800 niños menores de cinco años que morirían cada día para 2020. El parto prematuro y las complicaciones intraparto, así como las enfermedades infecciosas como la neumonía , la diarrea y la malaria, siguen siendo las principales causas de muerte entre los niños menores de cinco años en todo el mundo. Como resultado, las muertes entre los niños menores de cinco años requieren atención inmediata.

Data Bridge Market Research analiza que el mercado de medicamentos pediátricos se valoró en USD 117,20 mil millones en 2021 y se espera que alcance los USD 300,70 mil millones para 2029, registrando una CAGR del 12,5% durante el período de pronóstico de 2022 a 2029. El informe de mercado curado por el equipo de Data Bridge Market Research incluye un análisis experto en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Definición de mercado

A los pacientes de entre 2 y 12 años se les administran medicamentos pediátricos. La terapia pediátrica debe diferenciarse de la terapia para adultos, no sólo por la necesidad de adaptarse a distintos regímenes de dosificación, sino también porque la respuesta de un niño a un medicamento puede ser diferente a la de un adulto.

Alcance del informe y segmentación del mercado

Dinámica del mercado de medicamentos pediátricos

Conductores

• Aumento de la prevalencia de trastornos crónicos

Se estima que la creciente prevalencia de trastornos crónicos impulsará el crecimiento del mercado. Los trastornos crónicos como la anorexia, el asma , los defectos congénitos, las deficiencias del crecimiento, la diabetes, el cáncer infantil, la diabetes juvenil y el déficit de atención con hiperactividad, entre otros, son el principal factor que aumenta la demanda de medicamentos pediátricos, lo que influye en la dinámica del mercado durante el período de pronóstico de 2022 a 2029.

• Aumentar la inversión en infraestructura sanitaria

Otro factor importante que influye en la tasa de crecimiento del mercado de medicamentos pediátricos es el aumento del gasto sanitario, que contribuye a mejorar su infraestructura. Además, diversas organizaciones gubernamentales tienen como objetivo mejorar la infraestructura sanitaria aumentando la financiación, lo que influirá aún más en la dinámica del mercado.

Además, las crecientes iniciativas de organizaciones públicas y privadas para difundir la concienciación y la creciente incidencia de la obesidad entre los niños ampliarán el mercado de medicamentos pediátricos. Además, el cambio en el estilo de vida de las personas y el aumento de la población darán lugar a la expansión del mercado de medicamentos pediátricos.

Oportunidades

• Aumento del número de actividades de investigación y desarrollo       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the pediatric drugs market growth. The presence of many measures such as the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) is driving big businesses to enhance their R&D investments in pediatric drug research. Along with this, rising drug approvals and launches will further propel the market’s growth rate. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the pediatric drugs market growth during the forecast period.

Restraints/Challenges

On the other hand, the less number of study population and ethical issues in pediatric research will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the pediatric drugs market. Additionally, side effects associated with pediatric drugs including headache along with anxiety, and lack of awareness among people will act as restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This pediatric drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pediatric drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Pediatric drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Pediatric Drugs Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in several nations had imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The pediatric drugs market was hampered by the supply chain slowness.

Recent Development

• In October 2021, the United States Food and Drug Administration (FDA) announced the approval of Rethymic which is used for treating pediatric patients suffering from congenital athymia, a rare immune disorder. Rethymic is the first thymus tissue product approved in the United States.

Global Pediatric Drugs Market Scope

The pediatric drugs market is segmented on the basis of drug type, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Type

• Allergy and Respiratory Drugs
• Cancer Therapies
• Anti-Infectives
• Cardiovascular Drugs
• Gastrointestinal Drugs
• Central Nervous System Drugs
• Hormone Drugs
• Urological Drugs
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Pediatric Drugs Market Regional Analysis/Insights

The pediatric drugs market is analysed and market size insights and trends are provided by country, drug type, route of administration, end-users and distribution channel as referenced above.

The countries covered in the pediatric drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the pediatric drugs market because of the rising number of research activities in this region. Additionally, rising healthcare expenditure and presence of major key players will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to presence of generic manufacturers in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Pediatric Drugs Market Share Analysis

The pediatric drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pediatric drugs market.

Some of the major players operating in the pediatric drugs market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Zydus Cadila (India)
• AstraZeneca (UK)
• Johnson & Johnson (US)
• Bayer AG (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Bristol-Myers Squibb Company (US)
• Eli Lilly and Company (US)
• Cipla Inc. (US)
• Mallinckrodt (US)
• Apotex Inc. (Canada)
• Hikma Pharmaceuticals PLC (UK)
• Endo International plc (Ireland)

SKU-54463